What are the genes in PAM50?
PAM50 is a 50-gene signature that classifies breast cancer into five molecular intrinsic subtypes: Luminal A, Luminal B, HER2-enriched, Basal-like, and Normal-like (1, 5). Each of the five molecular subtypes varies by their biological properties and prognoses (6, 7).
What is PAM50 breast cancer?
PAM50 (Prosigna®) is a tumor profiling test that helps show whether some estrogen receptor-positive (ER-positive), HER2-negative breast cancers are likely to metastasize (when breast cancer spreads to other organs).
How do you classify breast cancer?
The current molecular classification divides breast cancer into five groups as luminal A, luminal B, HER-2, basal and normal breast like. Further grouping of these subgroups seem possible and necessary.
What is letrozole prescribed for?
Letrozole is a medicine used for treating breast cancer. It can also help prevent breast cancer coming back. It is mainly prescribed for women who have been through the menopause and have a type of cancer called “hormone-dependent” breast cancer.
Where is the first place breast cancer spreads?
The lymph nodes under your arm, inside your breast, and near your collarbone are among the first places breast cancer spreads. It’s “metastatic” if it spreads beyond these small glands to other parts of your body.
How are pam50 gene signatures used in clinical trials?
Clinical validation studies will assess the ability of PAM50 and other gene signatures to stratify patients and individualize treatment based on expected risks of distant recurrence. The clinical and genomic heterogeneity of early-stage breast cancer is well-recognized.
What are the prognostic factors for pam50 breast cancer?
The relationship between PAM50 intrinsic subtype and clinical prognostic factors was consistent with previous reports, including the enrichment of LumA cancers in postmenopausal patients and among smaller tumors. Randomized treatment assignment was well balanced across subtypes.
Which is better pam50 or CALGB 9741 intrinsic breast cancer?
PAM50 intrinsic breast cancer subtypes are prognostic independent of standard clinicopathologic factors. CALGB 9741 demonstrated improved recurrence-free (RFS) and overall survival (OS) with 2-weekly dose-dense (DD) versus 3-weekly therapy.
How are intrinsic subtypes of breast cancer prognostic?
PAM50 intrinsic breast cancer subtypes are prognostic independent of standard clinicopathologic factors. CALGB 9741 demonstrated improved recurrence-free (RFS) and overall survival (OS) with 2-weekly dose-dense (DD) versus 3-weekly therapy. A significant interaction between intrinsic subtypes and DD-therapy benefit was hypothesized.